Moderate Pain - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 87 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Moderate Pain - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Moderate Pain - Pipeline Review, H2 2014', provides an overview of the Moderate Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Moderate Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Moderate Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Moderate Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Moderate Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Moderate Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Moderate Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Moderate Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Moderate Pain Overview 9
Therapeutics Development 10
Pipeline Products for Moderate Pain - Overview 10
Pipeline Products for Moderate Pain - Comparative Analysis 11
Moderate Pain - Therapeutics under Development by Companies 12
Moderate Pain - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Moderate Pain - Products under Development by Companies 17
Moderate Pain - Companies Involved in Therapeutics Development 19
A. Menarini Industrie Farmaceutiche Riunite Srl 19
Acura Pharmaceuticals, Inc. 20
Aoxing Pharmaceutical Company, Inc 21
Egalet Corporation 22
INSYS Therapeutics, Inc. 23
KemPharm, Inc. 24
Kowa Company, Ltd. 25
Laboratorios Del Dr. Esteve S.A. 26
Nektar Therapeutics 27
Pain Therapeutics, Inc. 28
Pfizer Inc. 29
Relmada Therapeutics, Inc. 30
Trevena, Inc. 31
Moderate Pain - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 41
(acetaminophen + oxycodone hydrochloride) IR - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
(benzhydrocodone hydrochloride + acetaminophen) - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
(celecoxib + tramadol hydrochloride) - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
(dexketoprofen trometamol + tramadol hydrochloride) - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
(oxycodone hydrochloride + naltrexone) ER - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
buprenorphine hydrochloride - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
buprenorphine hydrochloride ER - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Egalet-003 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ELS-130 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
hydromorphone hydrochloride IR - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
K-103IP - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
levorphanol tartrate ER - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
methadone IR - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
morphine sulfate ER - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
morphine sulfate IR - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
NKTR-181 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
NKTR-194 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
oxycodone hydrochloride ER - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
oxycodone hydrochloride ER - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
oxymorphone IR - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
PTI-202 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
PTI-721 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
tilidine hydrochloride - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
tramadol hydrochloride IR - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
TRV-734 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Moderate Pain - Recent Pipeline Updates 71
Moderate Pain - Dormant Projects 82
Moderate Pain - Discontinued Products 83
Moderate Pain - Product Development Milestones 84
Featured News & Press Releases 84
Mar 04, 2014: KemPharm Expands Global Intellectual Property Estate for KP201 84
Feb 20, 2014: Egalet Receives Fast Track Designation for Egalet-001 84
Feb 20, 2014: Egalet Receives Fast Track Designation for Egalet-002 for Moderate to Severe Pain 84
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 87
Disclaimer 87

List of Tables
Number of Products under Development for Moderate Pain, H2 2014 10
Number of Products under Development for Moderate Pain - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Development by Companies, H2 2014 (Contd..1) 18
Moderate Pain - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2014 19
Moderate Pain - Pipeline by Acura Pharmaceuticals, Inc., H2 2014 20
Moderate Pain - Pipeline by Aoxing Pharmaceutical Company, Inc, H2 2014 21
Moderate Pain - Pipeline by Egalet Corporation, H2 2014 22
Moderate Pain - Pipeline by INSYS Therapeutics, Inc., H2 2014 23
Moderate Pain - Pipeline by KemPharm, Inc., H2 2014 24
Moderate Pain - Pipeline by Kowa Company, Ltd., H2 2014 25
Moderate Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2014 26
Moderate Pain - Pipeline by Nektar Therapeutics, H2 2014 27
Moderate Pain - Pipeline by Pain Therapeutics, Inc., H2 2014 28
Moderate Pain - Pipeline by Pfizer Inc., H2 2014 29
Moderate Pain - Pipeline by Relmada Therapeutics, Inc., H2 2014 30
Moderate Pain - Pipeline by Trevena, Inc., H2 2014 31
Assessment by Monotherapy Products, H2 2014 32
Assessment by Combination Products, H2 2014 33
Number of Products by Stage and Target, H2 2014 35
Number of Products by Stage and Mechanism of Action, H2 2014 37
Number of Products by Stage and Route of Administration, H2 2014 39
Number of Products by Stage and Molecule Type, H2 2014 40
Moderate Pain Therapeutics - Recent Pipeline Updates, H2 2014 71
Moderate Pain - Dormant Projects, H2 2014 82
Moderate Pain - Discontinued Products, H2 2014 83